One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Cellectar Biosciences, Inc.
CLRB · NCM · Healthcare · Biotechnology
Current price
$1.24
52-week range
$1.12 - $4.70
Market cap
$11.72M
Balance sheet
Healthy
-52.82x Concerning
Net cash $32.46M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -119.6% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 1.8% (peer median: 9.2%).
What this company does
Cellectar Biosciences, Inc.
Cellectar Biosciences is a company working on new cancer drugs, with its main focus on a treatment called CLR 131 which is currently being tested in patients. The money they make comes from research grants and investments because their drugs are still in the testing phase, and this matters because it shows how they fund their development of potentially life-saving treatments.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-9.17M
FY2024 Q4
$-10.97M
FY2025 Q4
$-4.35M
FY2026 Q1
$-4.85M
FY2026 Q2
$-6.01M
Revenue
—
Net income
$-6.93M
Diluted EPS
-0.57
Operating cash flow
$-6.01M
Free cash flow
$-6.01M
Fetching…
Sources
Revenue
—
Net income
$-5.65M
Diluted EPS
-1.33
Operating cash flow
$-4.85M
Free cash flow
$-4.85M
Fetching…
Sources
Revenue
—
Net income
$-5.30M
Diluted EPS
-3.41
Operating cash flow
$-4.34M
Free cash flow
$-4.35M
Fetching…
Sources
Revenue
—
Net income
$-4.44M
Diluted EPS
-1.41
Operating cash flow
$-4.28M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.45M
Diluted EPS
-3.39
Operating cash flow
$-5.12M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.60M
Diluted EPS
-0.14
Operating cash flow
$-9.38M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-7.42M
Diluted EPS
-0.08
Operating cash flow
$-10.91M
Free cash flow
$-10.97M
Fetching…
Sources
Revenue
—
Net income
$-14.66M
Diluted EPS
-0.40
Operating cash flow
$-9.17M
Free cash flow
$-9.17M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.24
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $32.5M - more cash than debt. Interest coverage -52.8x.
Net debt
$-32.46M
Interest coverage
-52.82x
Cellectar Biosciences, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
CLRB
BASELINE
Cellectar Biosciences, Inc.
Total debt $1.53M Interest coverage -52.82x This is the baseline the peer rows are being compared against.
Total debt $143.45K Interest coverage -18.51x Neither company has much profit cushion over interest right now.
Total debt $136.53K Interest coverage -14.62x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -16.17x Neither company has much profit cushion over interest right now.
Total debt $2.68M Interest coverage -58.49x Neither company has much profit cushion over interest right now.
Total debt $127.21K Interest coverage -303.37x Neither company has much profit cushion over interest right now.
What you should know
The case for and against CLRB
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -119.6% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 1.8% (peer median: 9.2%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.65x
P/B
0.34x
P/S
—
EV/EBITDA
0.90x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-119.6%
ROA
-58.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.05x
Current ratio
6.66x
Quick ratio
6.49x
Total debt
$1.53M
Total cash
$33.99M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-3.46
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-19.47M
Free CF TTM
$-23.12M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—